Atomoxetine
- Generic Name
- Atomoxetine
- Brand Names
- Strattera
- Drug Type
- Small Molecule
- Chemical Formula
- C17H21NO
- CAS Number
- 83015-26-3
- Unique Ingredient Identifier
- ASW034S0B8
- Background
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associat...
- Indication
Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Associated Therapies
- -
Atomoxetine and Executive Function in PTSD
- Conditions
- Interventions
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 160
- Registration Number
- NCT06573970
- Locations
- 🇺🇸
Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States
Black Seed Oil in ADHD
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 60
- Registration Number
- NCT06542887
Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT05550246
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Trial of AD113 and Atomoxetine in OSA Patients With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Apnimed
- Target Recruit Count
- 21
- Registration Number
- NCT04905979
- Locations
- 🇺🇸
PCCAB, Towson, Maryland, United States
🇺🇸Bogan Sleep Consultants, Columbia, South Carolina, United States
🇺🇸Intrepid Research, Cincinnati, Ohio, United States
Crossover Trial of AD109 in Obstructive Sleep Apnea
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Apnimed
- Target Recruit Count
- 60
- Registration Number
- NCT04580394
- Locations
- 🇺🇸
Preferred Research Partners, Inc., Little Rock, Arkansas, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸Teradan Clinical Trials, Brandon, Florida, United States
Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Brown University
- Target Recruit Count
- 42
- Registration Number
- NCT04565288
- Locations
- 🇺🇸
Brown University Center for Alcohol and Addiction Studies, Providence, Rhode Island, United States
Crossover Trial of AD036 in Obstructive Sleep Apnea
- Conditions
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Apnimed
- Target Recruit Count
- 62
- Registration Number
- NCT04445688
- Locations
- 🇺🇸
CTI Clinical Research Center, Cincinnati, Ohio, United States
🇺🇸Preferred Research Partners, Inc., Little Rock, Arkansas, United States
🇺🇸Sleep Medicine & Research Center, St. Luke's Hospital, Chesterfield, Missouri, United States
Atomoxetine in Patients With Tourette's Syndrome
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Poitiers University Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT04354103
- Locations
- 🇫🇷
Hospices civils de Lyon, Lyon, France
🇫🇷CHU Poitiers, Poitiers, France
🇫🇷AP-HP La Pitié Salpêtrière, Paris, France
Role of Coenzyme Q in ADHD in Children
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Sherief Abd-Elsalam
- Target Recruit Count
- 40
- Registration Number
- NCT04216186
- Locations
- 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt
A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 430000
- Registration Number
- NCT04132557
- Locations
- 🇺🇸
Janssen Investigative Site, Titusville, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.